ALLO NASDAQ
Allogene Therapeutics, Inc.
1W: -7.5%
1M: -24.5%
3M: -32.0%
YTD: -8.9%
1Y: +2.5%
3Y: -59.0%
5Y: -92.2%
$1.23
+0.02 (+1.65%)
Pre-Market: $1.25 (+0.02, +1.22%)
Weekly Expected Move ±6.5%
$1
$1
$1
$1
$1
Credit Risk of going bust: higher than 75% of companies Debt: 14.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 97%), Allogene Therapeutics, Inc. would be worth roughly what it owes.
Total debt $70.4M against a stock market value of $425.0M.
Distance to default 3.04 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $35.2M (short-term plus half of long-term), stock volatility 82.3%; Altman Z'' -6.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 97%), Allogene Therapeutics, Inc. would be worth roughly what it owes.
Total debt $70.4M against a stock market value of $425.0M.
Distance to default 3.04 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $35.2M (short-term plus half of long-term), stock volatility 82.3%; Altman Z'' -6.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-12-15
Earliest Filing
2025-02-25
Latest Filing
partner: 10
supplier: 2
investor: 1
Counterparties (Filed by ALLO)
13 relationshipsCompanies named in ALLO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Foresight Diagnostics, Inc. | — | partner | Amended and restated strategic collaboration agreement for MRD assay development as a companion diagnostic. | 2025-02-25 | View |
| Overland Pharmaceuticals (CY) Inc. | — | partner | Partner in the formation of the JV Company and party to the Share Exchange Agreement. | 2024-05-31 | View |
| Allogene Overland Biopharm (CY) Limited | — | partner | Joint Venture Company formed by the registrant and Overland. | 2024-05-31 | View |
| HH BioPharma Holdings Ltd. | — | investor | Acquired Overland's preferred shares in the JV Company and assumed obligations under the Share Exchange Agreement. | 2024-05-31 | View |
| Allogene Overland BioPharm (PRC) Co., Limited | — | partner | Indirect wholly owned subsidiary of the JV Company that became the Licensee under the amended Exclusive License Agreemen | 2024-05-31 | View |
| Notch Therapeutics, Inc. | — | partner | Amended and restated collaboration and license agreement regarding CAR targets and equity investments | 2024-01-31 | View |
| Foresight Diagnostics, Inc. | — | partner | Strategic Collaboration Agreement for MRD assay development and regulatory approval for cema-cel | 2024-01-05 | View |
| Britannia Pointe Grand Limited Partnership | — | supplier | Landlord for HQ Lease expansion premises | 2021-12-15 | View |
| Healthpeak Properties, Inc. | DOC | supplier | Landlord for HQ Lease extension | 2021-12-15 | View |
| Les Laboratoires Servier SAS | — | partner | Collaborator on Phase 1 ALPHA trials | 2021-12-15 | View |
| Institut de Recherches Internationales Servier SAS | — | partner | Collaborator on Phase 1 ALPHA trials | 2021-12-15 | View |
| SpringWorks Therapeutics | — | partner | Partner for investigational gamma secretase inhibitor nirogacestat | 2021-12-15 | View |
| Cellectis | CLLS | partner | Technology licensor for AlloCAR T programs | 2021-12-15 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-02 | Officer/Director Change | View | |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-06-22 | Shareholder Vote; Other Events | View | |
| 2026-05-28 | Officer/Director Change | View | |
| 2026-05-13 | Material Agreement; Termination of Agreement; Earnings Release; Exhibits | Agreement | View |
| 2026-04-15 | Other Events; Exhibits | View | |
| 2026-04-13 | Other Events | View | |
| 2026-04-13 | Other Events | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-14 | Other Events | View | |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-01 | Other Events | View | |
| 2025-06-23 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-25 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-01-29 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-11-13 | Other Events | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR